Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.36 | |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 4/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23498013 | 0.92 | HTR2A (0.39) | HTR2ASSTR3PDFALDH1A1MAPK1 | |
| SCHEMBL17490581 | 0.92 | HTR2A (0.39) | HTR2ASSTR3PDFALDH1A1MAPK1 | |
| SCHEMBL23498015 | 0.92 | HTR2A (0.39) | HTR2ASSTR3PDFALDH1A1MAPK1 | |
| SCHEMBL25976125 | 0.91 | HTR2A (0.39) | HTR2ASSTR3PDFALDH1A1MAPK1 | |
| SCHEMBL26015578 | 0.90 | SSTR3 (0.46) | HTR2ASSTR3FOLH1SIRT5SIRT1 | |
| SCHEMBL29589720 | 0.89 | SSTR3 (0.36) | HTR2ASSTR3PDFFURINFOLH1 | |
| SCHEMBL29423505 | 0.88 | HTR2A (0.45) | HTR2AALDH1A1MAPK1L3MBTL1ST6GAL1 | |
| SCHEMBL19731615 | 0.87 | FURIN (0.39) | HTR2ASSTR3PDFALDH1A1MAPK1 | |
| SCHEMBL22691442 | 0.87 | FURIN (0.39) | HTR2ASSTR3PDFALDH1A1MAPK1 | |
| SCHEMBL29649550 | 0.85 | PDF (0.38) | SSTR3PDFFURINFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | HTR2A 4236/4885SSTR3 3591/4885PDF 633/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | HTR2A 2703/4885SSTR3 1520/4885PDF 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.